Australia’s Acrux Biotech Set To Launch First Product In U.S.
This article was originally published in PharmAsia News
Acrux Limited, an Australia-based biotech, is about to launch its first product in the United States, its hormone-replacement EvaMist (estradiol) to treat menopause. KV Pharmaceuticals is handling marketing expected to begin in a few weeks. The firms expect about $1.5 billion in annual sales in the United States. EvaMist delivers estrogen by being sprayed on the skin, a technique believed to be more convenient for women. ("Click here for more
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.